ReviewAntibiotics (Basel, Switzerland)2022
Occidiofungin: Actin Binding as a Novel Mechanism of Action in an Antifungal Agent.
Review in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 9 citations in OpenAlex.
- 4-Hydroxy-3-Methyl-2-Alkenylquinoline Disrupts Temporospatial Control of Flagellar Assembly and Induces Transcriptomic Remodeling inMolecules (Basel, Switzerland) · 2026Article
- Biological control ofFrontiers in microbiology · 2026Article
- Ecological Diversity, Metabolic Versatility, and Biotechnological Applications ofAntibiotics (Basel, Switzerland) · 2025Review
- Recent advances in microbially derived chlorinated antiparasitic compounds.Molecular diversity · 2025Review
- Anti-AflatoxigenicMicroorganisms · 2024Article
- Intravaginal Gel for Sustained Delivery of Occidiofungin and Long-Lasting Antifungal Effects.Gels (Basel, Switzerland) · 2023Article
- Cloning and Molecular Characterization of theAntibiotics (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The identification and development of natural products into novel antimicrobial agents is crucial to combat the rise of multidrug-resistant microorganisms. Clinical fungal isolates have been identified, which have shown resistance to all current clinical antifungals, highlighting a significant need to develop a novel antifungal agent. One of the natural products produced by the bacterium
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.